Skip to content
Teethgrinder – Lifestyle
Author:
SystImmune, Inc.
SystImmune Announces First Patient Dosed in Global Phase 3 Trial of BL-M14D1 in First-Line Extensive-Stage Small Cell Lung Cancer
August 5, 2026
SystImmune Announces Second Approval of Iza-bren in China for the Treatment of Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
July 17, 2026
SystImmune Announces First Approval of Iza-bren for the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma in China
June 22, 2026
SystImmune Reports Phase 1 Data for BL-M14D1 Demonstrating Promising Activity in Small-Cell Lung Cancer at ASCO
June 1, 2026